A blog exploring pharmaceutical relationship marketing, emarketing and innovation with a focus on rare disorders.
SirenWired
The convergence of rare disease, digital communications, and pharmaceutical marketing communications

#SocPharm Tweetchat Transcript 5/4/2011

Posted by | 11:44pm on Wednesday, May 4, 2011

:
@ here from Novo Nordisk here to moderate this evening’s #socpharm Tweetchat. Thanks @ for the honor. :-) #socpharm

:
Welcome to the pharma/biotech marketing & social media chat (#socpharm). Plse introduce yourself when you arrive. #socpharm

:
We’ll assume that all tweets within #socpharm are your own and not your employers (unless you specifically declare them). #socpharm

:
@ big thanks for moderating #socpharm while I’m at #HBA #WOTY event in NYC

:
T1 this evening: How MDs like 2 interact with Pharma. “Sales reps still vital, say specialists & PCPs”: http://bit.ly/ml6aNy #socpharm

:
Hi. @ Glad to join tonight’s socpharm with @ and a congrats to @‘s Nifty50 Top Twitter Women award. #socpharm

:
Hi, happy to join tonight’s event. #socpharm

:
Congrats @! Way to twitter! #socpharm

:
RT @: Hi. @ Glad to join tonight’s socpharm with @ and a congrats to @‘s Nifty50 Top Twitter Women award. #socpharm

:
Wow, surprising stats -61% of PCPs and 50% of specialists “still maintain an open-door policy when it comes to sales rep visits” #socpharm

:
T1: Good read here about MDs still valuing reps but how is value migrating in age of few new prds and indication? #socpharm

:
@ @ thanks :) #socpharm

:
T1: @ Does % surprise you or how fast its evolving? Speed of evolution is what is most alarming if you ask me. #socpharm

:
Though access decline surprising, there will always be place for rep (as human) but what place is what we have to ponder. #socpharm

:
T1: greater value can come fr more digital/SM presence #socpharm @

:
Surprised at an open door policy. But you bring up a good point. With less prds/indications, will a rep detail on multi rx? #socpharm

:
@: I agree and believe that digital/SM will have even greater value when it get MD to relevant pharma human. :-) #socpharm

:
The place is the in-person value that can’t be delivered electronically, the personal exchange. Some things you can’t bottle up. #socpharm

:
Agree but more balance is needed @ #socpharm

:
~8 in 10 US doctors see drugmakers and their reps as useful sources of information on Rx medicines. I agree but, new not old. #socpharm

:
Agreed @ and digital/SM needs to be greater facilitator of the “personal exchange”. #socpharm

:
Key finding from L2 Pharma HCP study: Brands w/strong DTC digital mktg do not necessarily deliver to physicians online #socpharm

:
@ what is L2 definitin of “deliver to MDs online”? #socpharm

:
@ Yes, the tech facilitaties, the challenge is to keep it personal, relevant as @ points out for sure, balanced. #socpharm

:
The related article on GSK reps as #1 is nice given recent change in policy. http://bit.ly/fkzZZj #socpharm

:
I believe delivery of digital info @: #socpharm

:
@, when there is a person on the other end it is automatically personal, no? :-D #socpharm

:
Hi, a little late to tje convo but I see incongruency between research and real world. I think it is trending away sales reps. #socpharm

:
@ Eileen CONGRATS on #Nifty50 Top Twitter Women http://bit.ly/jHYvyM Well deserved! #socpharm @

:
FYI L2 study at: http://bit.ly/kEyQuz #socpharm

:
docs just don’t have time. They see value, but don’t have time. #socpharm

:
is the ‘free lunch’ sales reps bring an incentive to get in the door? #socpharm

:
@ When 1 says 2 little time (or 2 hi $) they really mean 2 little value. :-) #socpharm

:
@ the nurses love it. #socpharm

:
@ I think some people appreciate personal “connections” in diff ways. Think of the last time you received a written card #socpharm

:
@ Eileen #socpharm COMING in June more surprises – #Nifty50 Top Twitter Men & Social Pharma blogs ;-) #pharma #fdasm #hcsm #sm

:
@: I agree regarding trends. This survey is a snapshot in time. #socpharm

:
s @: #socpharm that has to be expensive for the reps

:
See Top Twitter Women #Nifty50 – Nurses? @: @ the nurses love it. #socpharm

:
@: Variety and choice are pillars of customer delight. We need to provide personal connections in diff ways for sure. #socpharm

:
@ What do you think about this Organized Wisdom content curation topic-have you heard much about it? http://bit.ly/jefjhF #socpharm

:
Should Your Doctor Be on Facebook? http://t.co/EOKhQn5 #socpharm | good idea?

:
Okay T2: Consumers trust health sites more than UGC. http://bit.ly/k6OtcB #socpharm

:
@: Yes my MD should definitely be on FB, but not my health records. #socpharm

:
RT @: Okay T2: Consumers trust health sites more than UGC. http://bit.ly/k6OtcB #socpharm makes sense/greater value

:
RT @: @: Yes my MD should definitely be on FB, but not my health records. #socpharm Good answer!

:
T2: I always think that ppl used UGC more for emotional support & networking and health sites for foundational information. #socpharm

:
@: T2: #socpharm AGREE

:
48% searched WebMD in the NYTimes article just referred to #socpharm

:
T2 agree @. People go to FB to express concerns, questions and opinions on treatment-the social side of discovery. #socpharm

:
T2: It seems those sites that are mix of health authority and UGC will do best. That is my hypothetical take on things. #socpharm

:
Related to health authority/experts, what do you think about Organized Wisdom? Some interesting claims here. http://bit.ly/jefjhF #socpharm

:
Is that a surprise? We forget our own behaviors when talking about health. I would go to mayo before a blog. #socpharm

:
T1: One more relevant link on this rep value topic, though oxymoronic. http://bit.ly/ioktKh #socpharm

:
RT @: Is that a surprise? We forget our own behaviors when talking about health. I would go to mayo before a blog. #socpharm

:
I would to go Mayo, then a blog, then to Twitter then to FB. :-) #socpharm

:
#socpharm for me Twitter may be an excellent first step…

:
@ You start with your doc, then Mayo, WebMD, then you turn to blogs and your friends/FB. A hierarchy of info seeking. #socpharm

:
@: Wow! I was not aware of these allegations regarding Organized Wisdom. I would love to hear their side of this story. #socpharm

:
important for mkters to understand the info path #socpharm @

:
@: I could actually check all these things on my tablet in the time I spend in the waiting room to see my MD. LOL! #socpharm

:
Study: 75% of U.S. physicians own some form of Apple device @ @ http://j.mp/lXy40x #socpharm

:
Quite the story, eh? Should we invite Simon Sikorski, MD and Organized Wisdom to next week’s chat? Intriguing for sure. #socpharm

:
@ Apple ownership stat not surprising when you consider their literacy and affluence. #socpharm

:
as a digital channel…. “Facebook Could Be Brand Marketer’s Dream” http://bit.ly/kVlVNl #socpharm

:
@: Question is how much meaningful medical use of these Apple devices are they making. #socpharm

:
@ if you know him feel free to extend an invite! #socpharm

:
@ #socpharm no doubt, still evolving but lots of promise from the devices

:
@ I think the healthcare info path is critical and we can’t lose sight of it. Think of @. #socpharm

:
@: I know Krein OW’s founder and can reach him for invite. Want me to? #socpharm

:
@ Think of @. #socpharm Agree.

:
Its not what device the doc is holding in her hand; its who owns it & what she is doing with it #socpharm

:
@ absolutely. #socpharm

:
One way to get to know him :^) It would make a great chat @: @ if you know him feel free to extend an invite! #socpharm

:
@ @ For the record, I prefer Android tablet to iPad for work. :-) #socpharm

:
Ok, T3: What you think about PatientsLikeMe Study Refuting Published ALS Clinical Trial: http://bit.ly/gwzvwW #socpharm

:
RT @: @ @ cool. how about a Xoom? #socpharm

:
@ invites OW and @ invites Dr Sikorski. Sounds like a plan! #socpharm

:
@: Xoom too big. I am loving my 7 inch Samsung Galaxy Tab Wifi, for work that is. I have iPad for play. #socpharm

:
@ How is the Samsung better for work? #socpharm

:
T3: So I saw J. Heywood talk about PLM as ClinTrial of future @ H2Con years ago and here we are with this article. Interesting. #socpharm

:
@: #Samsung Galaxy Tab better for single hand portability, data entry, font variability, better sharability, etc. #socpharm

:
The BlackBerry tablet is really the only disappointment; Galaxy tab fits in many a white lab coat pocket #socpharm

:
the iPad2 is amazing. All others still chasing the iPad1 #socpharm

:
Glad you asked ;-) 2 Social Media Pharma coming in June :-) @: @ What’s new at Blue Focus? #Nifty50 #socpharm #hcsm

:
@ @ Good to know. I don’t see getting rid of my iPad tomorrow, but nice to share your experience. #socpharm

:
@: Depends on criteria. iPad is chasing Android on portability & data entry. iPad trumps on other factors, agreed. #socpharm

:
BTW, I am looking to sell my iPad1 if you know anyone looking. #socpharm

:
@: I agree. BlackBerry Playbook is underwhelming & I hope they can get the corporate market on back of handhelds. #socpharm

:
With 10 minutes to go, any thoughts on PLM and ALS Trial? #socpharm

:
T3 Patients Like Me results – Great points re patient-centric research approach saving time, money http://bit.ly/lUKj1L #socpharm

:
@ The potential for faster more responsive trials in this (PLM) fashion is exciting possibility. #socpharm

:
Dag, I missed #socpharm again. @ looking forward to transcript. Hope u all had a great educational chat tonight!

:
Thx Craig. Well done. #socpharm

:
@ Agreed. Responsiveness and shorter time to results is very exciting. I think all CROs strive for this. #socpharm

:
Any topics you want us to consider for future tweetchats? #socpharm

:
Good job, Craig. Thx @: #socpharm

:
@ Thanks. #socpharm

:
@ U wanna sell ipad? Let’s chat DM. #socpharm. I’m in Philly too.

:
Will thing on new topics for next time. That’s for hosting @! #socpharm

:
@ Thanks. And thanks to all participants this evening. Have a blessed week and see you soon. #socpharm

:
#socpharm #Nifty50 – Suggestion for future discussions – THE FUTURE OF SOCIAL MEDIA PHARMA ;-)

:
Thanks again to @ for moderating #socpharm tonight. I’ll post transcript 2moro. Next week @ will b moderating.

:
@ depends on if ur at diagnosis or on therapy. IMHO – doc is often last step #socpharm

About Eileen O'Brien

Eileen has more than 16 years of digital healthcare marketing experience. She is an opinion leader on social media and biopharma, and has been invited to speak at industry conferences and quoted in publications.

View other posts from Eileen

Siren Interactive
  • Siren Interactive
  • Rare Disease Relationship Marketing Experts
  • 626 West Jackson Blvd, Suite 100
  • Chicago, IL 60661
  • 312.204.6700
  • 866.502.6714 (Toll Free)
  • www.sireninteractive.com